Bayer is breaking into the irritable bowel syndrome (IBS) therapy market with the acquisition of HiDoc Technologies, which ...

Moberg Pharma's Terclara fails Phase 3 trial for fungal nail infection maintenance dosing; Bayer exits partnership and ...

Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) did not meet the primary endpoint in the phase 3 study using 8 weeks of daily dosing followed by weekly maintenance dosing. The ...

UBS analyst Geoff Haire maintained a Hold rating on Bayer (0P6S – Research Report) today and set a price target of €22.00. The company’s shares ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Bayer (0P6S – Research Report) on December 3 and set a price target of €25.00.

Global agricultural adjuvants market was valued at US$ 3,924.92 million in 2023 and is projected to hit the market valuation of US$ 6,530.48 million by 2032 at a CAGR of 5.92% during the forecast ...

Dhanuka Agritech Ltd. is aiming to clock 18% growth in revenue and 20% increase in volume in fiscal 2025 on an aggregate ...

Triangle companies are leveraging advanced tools to address pressing global agricultural issues, from crop resilience to ...

Bayer has received regulatory authorisation for Plaxium, its first three-way formulation fungicide containing Iblon (isoflucypram). The news means Plaxium will be available to growers for use across a ...

"As you drive across the Midwest, maybe in the next seven, eight, 10 years, you're going to see a lot of this out there." ...

The first three-way fungicide co-formulation containing Iblon (isoflucypram) has gained approval for use in cereals, offering ...

Bayer CropScience has revised the record date for this corporate announcement to November 28, 2024. It was earlier set as ...